Novocure (NASDAQ: NVCR) today reported preliminary unaudited financial and operational results for the quarter and full year ended December 31, 2025. Novocure is a global oncology company working to ...
View source version on businesswire.com: https://www.businesswire.com/news/home/20260211177641/en/ ...
Change Change 4Q25 vs 3Q25 2025 vs 2024 Cash flow from operations excluding working capital (CFFO)(1) (B$) 7.2 +2% 27.8 -7% Adjusted net income (TotalEnergies share)(1) - in billions of dollars (B$) 3 ...
Operating profit for the fourth quarter of fiscal 2025 increased 106.1% to $606.3 million compared to $294.2 million in the fourth quarter of fiscal 2024. In the fourth quarter of fiscal 2024, the ...
1JV Inkai EBITDA is included in the uranium segment. See Financial results by segment - Uranium in our 2025 annual MD&A. The following Westinghouse financial outlook for 2025 is reported in US dollars ...
Organic revenues, comparable currency neutral operating income and comparable currency neutral EPS are non-GAAP financial measures. Refer to the Reconciliation of GAAP and Non-GAAP Financial Measures ...
Gross premiums written by the mortgage segment in the 2025 fourth quarter were 1.5% lower than in the 2024 fourth quarter, while net premiums written were 3.6% lower than in the 2024 fourth quarter.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results